Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease

Koutroubakis, Ioannis E.; Oustamanolakis, Pantelis; Karakoidas, Christos; Mantzaris, Gerassimos J.

doi:10.1007/s10620-009-1022-y

Cited by 40 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a single-arm study of 50 adult patients, LMWD was associated with an increase in hemoglobin of 1.7 g/dL from baseline after 4 weeks of therapy. Four patients experienced an adverse reaction to the test infusion dose, and one patient experienced an allergic reaction after the total dose was infused 51. None of these reactions left any residual effects.…”

Section: Management Of Iron Deficiency Anemiamentioning

confidence: 95%

Iron deficiency anemia in patients with inflammatory bowel disease

Goldberg

2013

CEG

View full text Add to dashboard Cite

Iron deficiency anemia is the most common form of anemia worldwide, caused by poor iron intake, chronic blood loss, or impaired absorption. Patients with inflammatory bowel disease (IBD) are increasingly likely to have iron deficiency anemia, with an estimated prevalence of 36%–76%. Detection of iron deficiency is problematic as outward signs and symptoms are not always present. Iron deficiency can have a significant impact on a patient’s quality of life, necessitating prompt management and treatment. Effective treatment includes identifying and treating the underlying cause and initiating iron replacement therapy with either oral or intravenous iron. Numerous formulations for oral iron are available, with ferrous fumarate, sulfate, and gluconate being the most commonly prescribed. Available intravenous formulations include iron dextran, iron sucrose, ferric gluconate, and ferumoxytol. Low-molecular weight iron dextran and iron sucrose have been shown to be safe, efficacious, and effective in a host of gastrointestinal disorders. Ferumoxytol is the newest US Food and Drug Administration-approved intravenous iron therapy, indicated for iron deficiency anemia in adults with chronic kidney disease. Ferumoxytol is also being investigated in Phase 3 studies for the treatment of iron deficiency anemia in patients without chronic kidney disease, including subgroups with IBD. A review of the efficacy and safety of iron replacement in IBD, therapeutic considerations, and recommendations for the practicing gastroenterologist are presented.

show abstract

Section: Management Of Iron Deficiency Anemiamentioning

confidence: 95%

Iron deficiency anemia in patients with inflammatory bowel disease

Goldberg

2013

CEG

View full text Add to dashboard Cite

show abstract

“…В связи с тем, что декстран является компонентом бактериаль-ной стенки, нередки аллергические реакции (0,5-5%), поэтому для железа декстрана необходимо проведение и введение тестовой дозы (25 мг) перед основной дозой [23,29].…”

Section: лечение анемииunclassified

“…Так, железа сахарат был более эффективен, чем пероральные препараты железа (прирост гемоглобина более 20 г/л наблюдался у 66% против 47% больных), и лучше переносился (частота побочных эффектов 4 и 24% соответственно) [29,30]. Показано, что разовые большие дозы элементного железа более эффективны по сравне-нию с неоднократным введением средних доз железа у пациентов с болезнью Крона.…”

Section: лечение анемииunclassified

Features of the anemia at patients with Crohn’s disease

Ахмедов¹,

Иванюк²,

Бикбавова³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

“…The total dose may require several hours to be administered, thus conditioning its use in outpatient treatment of IBD. 89 Two randomised controlled studies compared the efficacy and safety of IV iron sucrose and oral iron in patients with IBD. 77,78 In one study, 77 among the 91 patients enrolled, more patients in the group of IV iron completed the treatment (96% vs 76%, p = 0.0009) and had an increase in haemoglobin above 2.0 g/dL (66 % vs 47%; p = 0.07).…”

Section: Rationalementioning

confidence: 99%

Portuguese Consensus on the Diagnosis, Prevention and Treatment of Anaemia in Inflammatory Bowel Disease

et al. 2016

View full text Add to dashboard Cite

Introduction: Anaemia can be considered the most common extra-intestinal manifestation in inflammatory bowel disease. Nevertheless, anaemia is often under-diagnosed and under-treated both in adults and children with inflammatory bowel disease. Herein, we report the consensus statements on the management of anaemia in inflammatory bowel disease developed by the Portuguese Working Group on Inflammatory Bowel Disease (known as Grupo de Estudo da Doença Inflamatória Intestinal - GEDII) to aid clinicians in daily management of inflammatory bowel disease patients. Material and Methods: A comprehensive literature review was conducted in order to prepare consensus statements on the following topics: (1) prevalence and diagnosis of anaemia in inflammatory bowel disease, (2) iron supplementation for the prevention of anaemia in inflammatory bowel disease and (3) treatment of anaemia in inflammatory bowel disease. The final statements for each topic were discussed at a consensus meeting and rated according to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. Consensus: It was concluded that anaemia has a high incidence and prevalence in inflammatory bowel disease, particularly in those with active disease and hospitalised. Patients with anaemia had decreased quality of life and frequently complained of fatigue. Absolute indications for intravenous therapy should be considered: (1) moderate to severe anaemia (haemoglobin < 10.5 g/dL) or clearly symptomatic anaemia; (2) previous intolerance to oral iron supplements; (3) inappropriate response to oral iron; (4) active severe intestinal disease; (5) need for a quick therapeutic response (e.g. surgery in the short term); (6) concomitant therapy with erythropoiesis-stimulating agent; and (7) patient’s preference.

show abstract

Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease

Abstract: Total parenteral iron replacement with LMW iron dextran is an easy, safe, and effective alternative method for treating iron deficiency anemia in IBD. Harmless adverse reactions may develop in a minority of patients.

Cited by 40 publications

References 29 publications

Iron deficiency anemia in patients with inflammatory bowel disease

Iron deficiency anemia in patients with inflammatory bowel disease

Features of the anemia at patients with Crohn’s disease

Portuguese Consensus on the Diagnosis, Prevention and Treatment of Anaemia in Inflammatory Bowel Disease

Contact Info

Product

Resources

About